Covaxin’s booster dose is able to neutralise the vaccine evading Omicron variant of Covid-19, according to a study conducted at US’ Emory University, Bharat Biotech announced on Wednesday.
Earlier studies have demonstrated the neutralising potential of Covaxin against other SARS- COV-2 variants of concern such as Alpha, Beta, Delta, Zeta, and Kappa, it said.
The new study demonstrated “sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of neutralised the SARS-CoV-2 Omicron and Delta variants” the Hyderabad-based drug maker said in a statement.
The company said that the neutralisation activity seen among people boosted with Covaxin was comparable to what has been observed in mRNA vaccine-boosted people against the Omicron variant.
More than 90 percent of all individuals boosted with Covaxin showed neutralising antibodies. All participants received an initial two-dose schedule of Covaxin at Day 0 and Day 28. The study findings will soon be posted on preprint server medrxiv.